5'-甲氧基-3',4'-亚甲二氧基苯乙酮 | 66922-69-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 中文名称: 5'-甲氧基-3',4'-亚甲二氧基苯乙酮
• 英文名称: 1-(7-methoxybenzo[1,3]dioxol-5-yl)ethanone
• 英文别名: 1-(7-methoxy-benzo[1,3]dioxol-5-yl)-ethanone；3,4-Methylenedioxy-5-methoxy-acetophenone；3',4'-Methylendioxy-5'-methoxyacetophenon；Acetophenone, 5-methoxy-3,4-methylenedioxy-；1-(7-methoxy-1,3-benzodioxol-5-yl)ethanone
• CAS: 66922-69-8
• 化学式: C₁₀H₁₀O₄
• 分子量: 194.187
• InChiKey: MLPLZAMGYMIKDU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5'-甲氧基-3',4'-亚甲二氧基苯乙酮 、 对甲苯磺酰肼 以 乙醇 为溶剂， 以79%的产率得到N-[1-(7-methoxy-1,3-benzodioxol-5-yl)ethylideneamino]-4-methylbenzenesulfonamide
  参考文献：
  名称：

  Isocombretastatins A versus Combretastatins A: The Forgotten isoCA-4 Isomer as a Highly Promising Cytotoxic and Antitubulin Agent

  摘要：

  Herein is reported a convergent synthesis of isocombretastatins A, a novel class of potent antitubulin agents. These compounds having a 1,1-diarylethylene scaffold constitute the simplest isomers of natural Z-combretastatins A that are easy to synthesize without need to control the Z-olefin geometry. The discovery of isoCA-4 with biological activities comparable to that of CA-4 represents a major progress in this field.

  DOI：

  10.1021/jm900321u
• 作为产物：
  描述：

  1-(7-methoxybenzo[d][1,3]dioxol-5-yl)ethan-1-ol 在 二氧化锰 作用下， 以 二氯甲烷 为溶剂， 生成 5'-甲氧基-3',4'-亚甲二氧基苯乙酮
  参考文献：
  名称：

  Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases

  摘要：

  本发明提供了化合物I或II的化合物： 或其药学上可接受的衍生物，其中R 1 ，R 2 ，R 3 和R 4 如规范中所述。这些化合物是蛋白激酶的抑制剂，特别是JNK的抑制剂，JNK是一种参与细胞增殖、细胞死亡和对细胞外刺激反应的哺乳动物蛋白激酶；以及Src家族激酶，特别是Src和Lck激酶。这些化合物还是GSK3和CDK2激酶的抑制剂。本发明还涉及生产这些抑制剂的方法。本发明还提供了包括本发明的抑制剂的药物组合物以及利用这些组合物在治疗和预防各种疾病中的方法。

  公开号：

  US20030087922A1

文献信息

• Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20150231142A1

  公开（公告）日：2015-08-20

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及含有上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES
  申请人：Van Goor Fredrick F.

  公开号：US20110098311A1

  公开（公告）日：2011-04-28

  The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

  本发明涉及包含上皮钠通道活性抑制剂与至少一种ABC转运蛋白调节剂化合物（A式、B式、C式或D式）的药物组合物。该发明还涉及这些药物配方，以及使用这些组合物治疗CFTR介导的疾病，特别是囊性纤维化的方法。
• Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases
  申请人：——

  公开号：US20030087922A1

  公开（公告）日：2003-05-08

  The present invention provide a compound of formula I or II: 1 or a pharmaceutically acceptable derivative thereof, wherein R 1 , R 2 , R 3 , and R 4 are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli; and Src-family kinases, especially Src and Lck kinases. These compounds are also inhibitors of GSK3 and CDK2 kinases. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.

  本发明提供了化合物I或II的化合物： 或其药学上可接受的衍生物，其中R 1 ，R 2 ，R 3 和R 4 如规范中所述。这些化合物是蛋白激酶的抑制剂，特别是JNK的抑制剂，JNK是一种参与细胞增殖、细胞死亡和对细胞外刺激反应的哺乳动物蛋白激酶；以及Src家族激酶，特别是Src和Lck激酶。这些化合物还是GSK3和CDK2激酶的抑制剂。本发明还涉及生产这些抑制剂的方法。本发明还提供了包括本发明的抑制剂的药物组合物以及利用这些组合物在治疗和预防各种疾病中的方法。
• [EN] MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS<br/>[FR] MODULATEURS DES TRANSPORTEURS DE LA CASSETTE DE LIAISON À L'ATP
  申请人：VERTEX PHARMA

  公开号：WO2010054138A2

  公开（公告）日：2010-05-14

  Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

  本发明的化合物及其药学上可接受的组成物，可作为ATP结合盒（“ABC”）转运蛋白或其片段的调节剂，包括囊性纤维化跨膜传导调节因子（“CFTR”）。本发明还涉及使用本发明的化合物治疗ABC转运蛋白介导的疾病的方法。
• Arylamine Ketones, Their Preparation Methods, The Pharmaceutical Composition Containing Them And Their Use
  申请人：Zhu Liya

  公开号：US20080221106A1

  公开（公告）日：2008-09-11

  Disclosed Arylamine ketones of formula (I), their preparation methods, the pharmaceutical compositions containing them and their use in preventing and/or treating the diseases related to the plaque-activating factors, especially in anti-inflammation and immunization, more especially in the treatment of the acute or chronic inflammation, such as, osteoarthritis, oarthritis deformans, etc.

  公开了式（I）的芳基胺酮化合物，它们的制备方法，含有它们的药物组合物以及在预防和/或治疗与斑块活化因子有关的疾病中的应用，特别是在抗炎和免疫方面，更特别地用于治疗急性或慢性炎症，如骨关节炎，变形性骨关节炎等。